Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiratricol Treatment of Children with Monocarboxylate Transporter 8 Deficiency: Triac Trial II

Next Previous
Trial Profile

Tiratricol Treatment of Children with Monocarboxylate Transporter 8 Deficiency: Triac Trial II

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiratricol (Primary)
  • Indications Allan-Herndon-Dudley syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms Triac Trial II
  • Sponsors Rare Thyroid Therapeutics

Most Recent Events

  • 13 Feb 2025 The EU approval is applicable to all 27 European Union member states, as well as Iceland, Norway, and Liechtenstein.
  • 13 Feb 2025 According to Egetis Therapeutics media release, the company announced that the European Commission (EC) has approved Emcitate (tiratricol) for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency. The approval of Emcitate is primarily based on Triac Trial I, supported by The Erasmus University Medical Center Cohort Study, and preliminary results of Triac Trial II.
  • 19 Jun 2024 According to Egetis media release, data will be presented at a forthcoming medical meeting, submitted to a peer-reviewed medical journal and shared with regulatory authorities. Results from Triac Trial II and will be included in the response to EMA 120-day list of questions in August 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top